Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed by Lilu Anderson 25.06.2024 Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Novo Nordisk’s $4.1B Clayton Facility to Add 1,000 Jobs by Mark Eisenberg 25.06.2024 Novo Nordisk's $4.1B Clayton investment creates 1,000 jobs, boosts local economy, and enhances life science growth in North Carolina.
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Zealand Pharma Surges on Promising Weight Loss Drug Trial Results by Mark Eisenberg 21.06.2024 Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
NHS Chief: Regulate Crypto to Curb Rising Gambling Crisis by John Darbie 17.06.2024 NHS chief urges tighter cryptocurrency controls, citing rise in gambling issues potentially escalating NHS service demand. — The Telegraph, June ...
Altimmune’s Promising GLP-1 Drug: Worth the Investment? by Mark Eisenberg 25.04.2024 Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Pfizer’s Debt Concerns Cast Doubt on Viking Therapeutics Acquisition by Mark Eisenberg 01.04.2024 Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
Top Stocks to Buy in April: Viking, Brookfield Renewable, & UPS by Mark Eisenberg 31.03.2024 Investors seeking a blend of growth, income, and value should consider Viking, Brookfield Renewable, and UPS. While UPS faced a ...